Last 12 months
Inside the activity.
0 purchase rows · 57 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 16 |
| Dec 2025 | 0 | 12 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 9 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2019 Filed Dec 9, 2019 21:17 UTC |
Hanna John Walter JRChief Commercial Officer
|
SaleCommon Stock | 9,838 | $30.09 | $295,994.92 |
DisclosureSEC source: 0001384101-19-000162 · wf-form4_157592621292255.xml · nonDerivative · entry 4 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,275 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.55. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 21:17 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionCommon Stock | 9,838 | $9.05 | $89,033.90 |
DisclosureSEC source: 0001384101-19-000162 · wf-form4_157592621292255.xml · nonDerivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 21:12 UTC |
Kennedy KeithCOO / CFO
|
SaleStock Option (right to buy) · Derivative | 13,851 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001384101-19-000158 · wf-form4_157592591191238.xml · derivative · entry 8 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,842 Underlying: Common Stock · 13,851 shares Expires 2026-12-05 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F4 · derivative.exercise_date: Beginning on December 6, 2017, 1/36 of the of shares vest each month for the following 36 months. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 21:12 UTC |
Kennedy KeithCOO / CFO
|
SaleCommon Stock | 13,851 | $30.04 | $416,146.37 |
DisclosureSEC source: 0001384101-19-000158 · wf-form4_157592591191238.xml · nonDerivative · entry 5 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,703 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.50. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 21:12 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionCommon Stock | 13,851 | $7.47 | $103,466.97 |
DisclosureSEC source: 0001384101-19-000158 · wf-form4_157592591191238.xml · nonDerivative · entry 4 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:19 UTC |
JONES EVAN/ FADirector
|
SaleCommon Stock | 5,151 | $30.00 | $154,535.15 |
DisclosureSEC source: 0001384101-19-000164 · wf-form4_157592633992380.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 174,502 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.000 to $30.005. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:17 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,100 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000162 · wf-form4_157592621292255.xml · derivative · entry 5 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,630 Underlying: Common Stock · 8,100 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F4 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:17 UTC |
Hanna John Walter JRChief Commercial Officer
|
SaleCommon Stock | 8,100 | $30.01 | $243,046.98 |
DisclosureSEC source: 0001384101-19-000162 · wf-form4_157592621292255.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,275 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.02. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:17 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionCommon Stock | 8,100 | $9.05 | $73,305.00 |
DisclosureSEC source: 0001384101-19-000162 · wf-form4_157592621292255.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:15 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 32,803 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001384101-19-000160 · wf-form4_157592610410859.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 32,803 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:15 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 32,803 | $29.39 | $964,142.50 |
DisclosureSEC source: 0001384101-19-000160 · wf-form4_157592610410859.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,862 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $29.34 to $29.56. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:15 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 32,803 | $14.34 | $470,395.02 |
DisclosureSEC source: 0001384101-19-000160 · wf-form4_157592610410859.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:12 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,358 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000158 · wf-form4_157592591191238.xml · derivative · entry 7 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,892 Underlying: Common Stock · 7,358 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:12 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionStock Option (right to buy) · Derivative | 11,942 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001384101-19-000158 · wf-form4_157592591191238.xml · derivative · entry 6 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,693 Underlying: Common Stock · 11,942 shares Expires 2026-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F4 · derivative.exercise_date: Beginning on December 6, 2017, 1/36 of the of shares vest each month for the following 36 months. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:12 UTC |
Kennedy KeithCOO / CFO
|
SaleCommon Stock | 19,300 | $30.00 | $579,069.48 |
DisclosureSEC source: 0001384101-19-000158 · wf-form4_157592591191238.xml · nonDerivative · entry 3 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,703 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.03. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:12 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionCommon Stock | 7,358 | $5.98 | $44,000.84 |
DisclosureSEC source: 0001384101-19-000158 · wf-form4_157592591191238.xml · nonDerivative · entry 2 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:12 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionCommon Stock | 11,942 | $7.47 | $89,206.74 |
DisclosureSEC source: 0001384101-19-000158 · wf-form4_157592591191238.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · derivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,657 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F7 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,312 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · derivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,563 Underlying: Common Stock · 5,312 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F6 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,563 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · derivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,085 Underlying: Common Stock · 1,563 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F5 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,751 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,752 Underlying: Common Stock · 3,751 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F4 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 15,327 | $26.47 | $405,662.77 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,862 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.99 to $26.94. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 5,312 | $9.05 | $48,073.60 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 1,563 | $5.43 | $8,487.09 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 21:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 3,751 | $6.45 | $24,193.95 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:24 UTC |
Hanna John Walter JRChief Commercial Officer
|
Tax withholdingCommon Stock | 217 | $27.19 | $5,900.23 |
DisclosureSEC source: 0001384101-19-000154 · wf-form4_157549465021571.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,275 F1 · shares: The reporting person is reporting the withholding of 217 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 437 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:26 UTC |
Ho MarkPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 65 | $27.19 | $1,767.35 |
DisclosureSEC source: 0001384101-19-000156 · wf-form4_157549477284478.xml · nonDerivative · entry 1 Ho Mark · CIK 0001554165 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,758 F1 · shares: The reporting person is reporting the withholding of 65 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 187 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:18 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 988 | $27.19 | $26,863.72 |
DisclosureSEC source: 0001384101-19-000148 · wf-form4_157549429418203.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,738 F1 · shares: The reporting person is reporting the withholding of 988 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,875 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:20 UTC |
Kennedy KeithCOO / CFO
|
Tax withholdingCommon Stock | 340 | $27.19 | $9,244.60 |
DisclosureSEC source: 0001384101-19-000150 · wf-form4_157549441517000.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,703 F1 · shares: The reporting person is reporting the withholding of 340 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 644 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 21:22 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Tax withholdingCommon Stock | 292 | $27.19 | $7,939.48 |
DisclosureSEC source: 0001384101-19-000152 · wf-form4_157549452516750.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,157 F1 · shares: The reporting person is reporting the withholding of 292 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:13 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,697 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001384101-19-000144 · wf-form4_157532119634376.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,303 Underlying: Common Stock · 3,697 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:13 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 3,697 | $29.36 | $108,534.31 |
DisclosureSEC source: 0001384101-19-000144 · wf-form4_157532119634376.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,449 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $29.34 to $29.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:13 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 3,697 | $14.34 | $53,014.98 |
DisclosureSEC source: 0001384101-19-000144 · wf-form4_157532119634376.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:30 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,753 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000142 · wf-form4_157489023384890.xml · derivative · entry 10 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,730 Underlying: Common Stock · 10,753 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F5 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018 and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:30 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,744 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001384101-19-000142 · wf-form4_157489023384890.xml · derivative · entry 9 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,332 Underlying: Common Stock · 4,744 shares Expires 2025-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:30 UTC |
Hanna John Walter JRChief Commercial Officer
|
SaleCommon Stock | 15,497 | $28.55 | $442,479.64 |
DisclosureSEC source: 0001384101-19-000142 · wf-form4_157489023384890.xml · nonDerivative · entry 6 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,492 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.50 to $28.81. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:30 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionCommon Stock | 10,753 | $9.05 | $97,314.65 |
DisclosureSEC source: 0001384101-19-000142 · wf-form4_157489023384890.xml · nonDerivative · entry 5 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:30 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionCommon Stock | 4,744 | $8.86 | $42,031.84 |
DisclosureSEC source: 0001384101-19-000142 · wf-form4_157489023384890.xml · nonDerivative · entry 4 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:30 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,517 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000142 · wf-form4_157489023384890.xml · derivative · entry 8 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,483 Underlying: Common Stock · 1,517 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F5 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018 and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:30 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 924 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001384101-19-000142 · wf-form4_157489023384890.xml · derivative · entry 7 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,076 Underlying: Common Stock · 924 shares Expires 2025-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:30 UTC |
Hanna John Walter JRChief Commercial Officer
|
SaleCommon Stock | 2,441 | $28.52 | $69,609.51 |
DisclosureSEC source: 0001384101-19-000142 · wf-form4_157489023384890.xml · nonDerivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,492 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.50 to $28.54. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:30 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionCommon Stock | 1,517 | $9.05 | $13,728.85 |
DisclosureSEC source: 0001384101-19-000142 · wf-form4_157489023384890.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:30 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionCommon Stock | 924 | $8.86 | $8,186.64 |
DisclosureSEC source: 0001384101-19-000142 · wf-form4_157489023384890.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:28 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionStock Option (right to buy) · Derivative | 18,757 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000140 · wf-form4_157489009934158.xml · derivative · entry 3 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,250 Underlying: Common Stock · 18,757 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F3 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:28 UTC |
Kennedy KeithCOO / CFO
|
SaleCommon Stock | 18,757 | $28.01 | $525,475.48 |
DisclosureSEC source: 0001384101-19-000140 · wf-form4_157489009934158.xml · nonDerivative · entry 2 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,043 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.00 to $28.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:28 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionCommon Stock | 18,757 | $5.98 | $112,166.86 |
DisclosureSEC source: 0001384101-19-000140 · wf-form4_157489009934158.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:38 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 19,571 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000138 · wf-form4_157420306616176.xml · derivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,338 Underlying: Common Stock · 19,571 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F3 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:38 UTC |
Hanna John Walter JRChief Commercial Officer
|
SaleCommon Stock | 19,571 | $25.18 | $492,787.99 |
DisclosureSEC source: 0001384101-19-000138 · wf-form4_157420306616176.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,492 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.86 to $25.61. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:38 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionCommon Stock | 19,571 | $6.45 | $126,232.95 |
DisclosureSEC source: 0001384101-19-000138 · wf-form4_157420306616176.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.